Abstract CT014: Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 studyIván Márquez‐Rodas, Stéphane Dalle, Luis de la Cruz‐Merino et al.|Cancer Research|2022Cited by 6